Takeda and Lundbeck Announce FDA Approval of Brintellix™ (vortioxetine) for Treatment of Adults with Major Depressive Disorder
Takeda and Lundbeck Announce FDA Approval of Brintellix™ (vortioxetine) for Treatment of Adults with Major Depressive Disorder. Osaka, Japan and Copenhagen, Denmark—October 1, 2013—Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today that the U.S. Food and Drug Administration (FDA) has approved Brintellix (vortioxetine) for the treatment of adults with major […]